Prosecution Insights
Last updated: November 04, 2026
Application No. 18/978,955

Zonal and Targeted Methods and Uses for Treating a Post-Traumatic Stress Disorder

Non-Final OA §112§DOUBLEPATENT
Filed
Dec 12, 2024
Priority
Jun 03, 2020 — provisional 63/034,215 +1 more
Examiner
SWIFT, CANDICE LEE
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Miotox LLC
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
74 granted / 131 resolved
-3.5% vs TC avg
Strong +38% interview lift
Without
With
+38.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
49 currently pending
Career history
194
Total Applications
across all art units

Statute-Specific Performance

§101
9.9%
-30.1% vs TC avg
§103
28.8%
-11.2% vs TC avg
§102
9.4%
-30.6% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 131 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-26 are pending and under examination on their merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 25 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 25 recites the post-traumatic brain injury is a mild, moderate or severe injury. However, these alternatives appear to encompass all severities of post-traumatic brain injury. Therefore, claim 25 fails to further limit the subject matter of claim 1, from which claim 25 depends. Applicant may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 12,364,740 (hereafter ‘740) in view of Smitherman et al. (Current treatment options in neurology 16.10 (2014): 312). Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘740 recites a method for treating a chronic post-traumatic headache. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 22 of ‘740 recites a method for treating a chronic post-traumatic headache associated with a post-traumatic brain injury. Claim 1 of ‘740 does not recite that the chronic post-traumatic headache is associated with the post-traumatic brain injury or that the chronic post-traumatic headache is a migraine. Claim 22 of ‘740 does not recite that the chronic post-traumatic headache is a migraine. Smitherman teaches that chronic daily headache (CDH) is an umbrella term referring to any headache disorder that occurs on 15 or more days per month (page 1, Introduction, left column, Chronic daily headache paragraph 1). Most individuals with CDH present with chronic migraine or chronic tension-type headache (page 1, Introduction, left column, Chronic daily headache paragraph 1). Smitherman teaches that PTSD is often comorbid with chronic migraine and chronic tension-type headache and that botulinum toxin A is efficacious for the treatment of CDH (Opinion statement page 1). Smitherman teaches that head injury is a secondary cause of CDH (page 6, Treatment of CDH (CM and CTTH), paragraph 1). Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘740 or claim 22 of ‘740 to treat symptoms of a migraine associated with a post-traumatic brain injury in an individual. The person of ordinary skill in the art would have recognized based on Smitherman that chronic post-traumatic headaches, which are either migraines or tension-type headaches, are associated with post-traumatic brain injuries such as concussion. The person of ordinary skill in the art would have had a reasonable expectation of success in treating symptoms of a migraine associated with a post-traumatic brain injury because Smitherman teaches that botulinum toxin A is efficacious for the treatment of CDH and the methods of claim 1 and 22 of ‘740 are botulinum toxin injection protocols. Each of instant claims 2-21 are obvious over each of claims 2-21 of ‘740, respectively, in view of Smitherman. Regarding instant claim 22, claims 1 and 22 of ‘740 do not recite that the chronic post-traumatic headache is a migraine associated with a concussion. Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the methods of claim 1 or 22 of ‘740 by specifically treating a migraine subsequent to a concussion. The person of ordinary skill in the art would have been motivated by the teachings of Smitherman, who teaches that CDH encompasses migraines (page 1, Introduction, left column, Chronic daily headache paragraph 1), CDH can occur subsequent to a concussion (page 2, left column, Trauma, PTSD, and CDH, paragraph 1), and botulinum toxin is efficacious in the treatment of CDH (Opinion statement page 1). The person of ordinary skill in the art would have had a reasonable expectation of success given that the methods of claim 1 and 22 of ‘740 are botulinum toxin injection protocols. Instant claim 23 is obvious over claims 24 and 26 of ‘740 in view of Smitherman. Although claims 24 and 26 of ‘740 recite treating a chronic post-traumatic headache associated with post-traumatic brain injury or PTSD rather than specifically treating a migraine, Smitherman teaches that chronic daily headache, which encompasses migraines, are associated with concussion (i.e. post-traumatic brain injury; see Smitherman page 2, left column, Trauma, PTSD, and CDH, paragraph 1). Therefore, it would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to treat migraines associated with the recited post-traumatic brain injuries and the person of ordinary skill in the art would have had a reasonable expectation of success in doing so. Regarding instant claim 24, claims 1 and 22 of ‘740 do not recite that the individual was nonresponsive to another Botulinum toxin treatment. However, it would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to apply the method of claims 1 or 22 of ‘740 to an individual who was nonresponsive to another Botulinum toxin treatment, such as a treatment with a lower dose of Botulinum toxin, in order to treat the migraine. The person of ordinary skill in the art would have had a reasonable expectation of success given that the methods of claim 1 and 22 of ‘740 recite high doses of Botulinum toxin (e.g. at least 30 units of the Botulinum toxin are administered to the left occipital nerve cluster zone and at least 30 units of the Botulinum toxin are administered to the right occipital nerve cluster zone). Instant claim 25 is obvious over claims 1 and 22 of ‘740 in view of Smitherman. Claim 26 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 22 of U.S. Patent No. 12,364,740 (hereafter ‘740) in view of Glenn et al. (Traumatic brain injury: a clinician’s guide to diagnosis, management, and rehabilitation. Cham: Springer International Publishing, 2019. 293-327. Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘740 recites a method for treating a chronic post-traumatic headache. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 22 of ‘740 recites a method for treating a chronic post-traumatic headache associated with a post-traumatic brain injury. Claims 1 and 22 of ‘740 do not recite that the chronic post-traumatic headache is associated with post-concussion syndrome or that the chronic post-traumatic headache is a migraine. Glenn teaches that mild traumatic brain injury can be associated with a variety of symptoms and the term “post-concussion syndrome” has been frequently used to describe the complex cognitive, physical and emotional complaints that can occur (page 309, left column, “Post-Concussion Symptoms,” paragraph 1). The most frequent complaints include headaches (page 309, “Post-Concussion Symptoms,” right column, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘740 by treating a migraine associated with post-concussion syndrome. The person of ordinary skill in the art would have been motivated by the teaching of Glenn, who suggests that headaches are frequently experienced by individuals with post-concussion syndrome. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘740 is a botulinum injection protocol for treating a chronic post-traumatic headache. Claims 1-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 12,533,400 (hereafter ‘400) in view of Smitherman et al. (Current treatment options in neurology 16.10 (2014): 312). Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘400 recites a method for treating a chronic post-traumatic headache associated with a post-traumatic stress disorder. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 22 of ‘400 recites the chronic post-traumatic headache is chronic post-traumatic migraine. Claim 1 of ‘400 does not recite that the chronic post-traumatic headache is a migraine or that the migraine is associated with a post-traumatic brain injury. Claim 22 of ‘400 does not recite that the chronic post-traumatic migraine is associated with a post-traumatic brain injury. Smitherman teaches that chronic daily headache (CDH) is an umbrella term referring to any headache disorder that occurs on 15 or more days per month (page 1, Introduction, left column, Chronic daily headache paragraph 1). Most individuals with CDH present with chronic migraine or chronic tension-type headache (page 1, Introduction, left column, Chronic daily headache paragraph 1). Smitherman teaches that PTSD is often comorbid with chronic migraine and chronic tension-type headache and that botulinum toxin A is efficacious for the treatment of CDH (Opinion statement page 1). Smitherman teaches that head injury is a secondary cause of CDH (page 6, Treatment of CDH (CM and CTTH), paragraph 1). Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claims 1 or 22 of ‘400 by treating a migraine associated with a post-traumatic brain injury. The person of ordinary skill in the art would have recognized based on the teachings of Smitherman that chronic headaches are either tension-type or migraines and are associated with both head injury (encompasses brain injury) and PTSD. The person of ordinary skill in the art would have had a reasonable expectation of success because Smitherman teaches that botulinum toxin A is efficacious for the treatment of CDH and the methods of claims 1 and 22 of ‘400 are botulinum toxin injection protocols. Each of instant claims 2-21 are obvious over each of claims 2-21 of ‘400, respectively, in view of Smitherman. Regarding instant claim 22, claim 1 of ‘400 also does not recite that the chronic post-traumatic headache is a migraine associated with a concussion. Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘400 by specifically treating a migraine subsequent to a concussion. The person of ordinary skill in the art would have been motivated by the teachings of Smitherman, who teaches that CDH encompasses migraines (page 1, Introduction, left column, Chronic daily headache paragraph 1), CDH can occur subsequent to a concussion (page 2, left column, Trauma, PTSD, and CDH, paragraph 1), and botulinum toxin is efficacious in the treatment of CDH (Opinion statement page 1). The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘400 is a botulinum toxin injection protocol. Regarding instant claim 23¸ claim 1 of ‘400 does not recite that the chronic post-traumatic headache associated with PTSD is a migraine or that the migraine is also associated with a post-traumatic brain injury. However, Smitherman teaches migraines associated with PTSD as well as migraines associated with concussion and military service (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). Therefore, it would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘400 to treat migraines in individuals with both post-traumatic brain injury such as concussion as well as PTSD, since migraines are associated with both conditions. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘400 is a botulinum toxin injection protocol for treating migraines and Smitherman also teaches that botulinum toxin is efficacious in treating chronic daily headache (page 1, Opinion Statement), which includes migraines. Regarding instant claim 24, claim 1 of ‘400 does not recite that the individual was nonresponsive to another Botulinum toxin treatment. However, it would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to apply the method of claim 1 of ‘400 to an individual who was nonresponsive to another Botulinum toxin treatment, such as a treatment with a lower dose of Botulinum toxin, in order to treat the migraine. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘400 recites high doses of Botulinum toxin (e.g. at least 30 units of the Botulinum toxin are administered to the left occipital nerve cluster zone and at least 30 units of the Botulinum toxin are administered to the right occipital nerve cluster zone). Instant claim 25 is obvious over claim 1 of ‘400 in view of Smitherman since Smitherman teaches that head injury is a secondary cause of CDH (page 6, Treatment of CDH (CM and CTTH), paragraph 1). A head injury that causes a CDH (encompasses migraines) is a type of post-traumatic brain injury. Claim 26 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,533,400 (hereafter ‘400) in view of Glenn et al. (Traumatic brain injury: a clinician’s guide to diagnosis, management, and rehabilitation. Cham: Springer International Publishing, 2019. 293-327. Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘400 recites a method for treating a chronic post-traumatic headache associated with a post-traumatic stress disorder. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 1 of ‘400 does not recite that the chronic post-traumatic headache is associated with post-concussion syndrome or that the chronic post-traumatic headache is a migraine. Glenn teaches that mild traumatic brain injury can be associated with a variety of symptoms and the term “post-concussion syndrome” has been frequently used to describe the complex cognitive, physical and emotional complaints that can occur (page 309, left column, “Post-Concussion Symptoms,” paragraph 1). The most frequent complaints include headaches (page 309, “Post-Concussion Symptoms,” right column, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘400 by treating a migraine associated with post-concussion syndrome. The person of ordinary skill in the art would have been motivated by the teaching of Glenn, who suggests that headaches are frequently experienced by individuals with post-concussion syndrome. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘400 is a botulinum injection protocol for treating a chronic post-traumatic headache. Claims 1-25 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-11, 14-16, 20-22, 26-27, and 31-35 of U.S. Patent No. 12,178,862 (hereafter ‘862) in view of Smitherman et al. (Current treatment options in neurology 16.10 (2014): 312). Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘862 recites a method for treating a migraine disorder. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 1 of ‘862 does not recite that the migraine is associated with a post-traumatic brain injury. Smitherman teaches that chronic daily headache (CDH) is an umbrella term referring to any headache disorder that occurs on 15 or more days per month (page 1, Introduction, left column, Chronic daily headache paragraph 1). Most individuals with CDH present with chronic migraine or chronic tension-type headache (page 1, Introduction, left column, Chronic daily headache paragraph 1). Smitherman teaches that PTSD is often comorbid with chronic migraine and chronic tension-type headache and that botulinum toxin A is efficacious for the treatment of CDH (Opinion statement page 1). Smitherman teaches that head injury is a secondary cause of CDH (page 6, Treatment of CDH (CM and CTTH), paragraph 1). Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘862 to specifically treat a migraine associated with a post-traumatic brain injury. The person of ordinary skill in the art would have been motivated by the teachings of Smitherman, who suggests that chronic daily headache or CDH, which encompasses migraines, is associated with head injury. The person of ordinary skill in the art would have had a reasonable expectation of success given that Smitherman teaches that botulinum toxin A is efficacious for the treatment of CDH and the method of claim 1 of ‘862 is a botulinum toxin injection protocol. Instant claim 2 is obvious over claim 4 of ‘862 in view of Smitherman. The range of 40 to 60 units overlaps with the presently claimed range of 50 to 60 units. Instant claim 3 is obvious over claim 5 of ‘862 in view of Smitherman. Instant claim 4 is obvious over claim 6 of ‘862 in view of Smitherman. Instant claim 5 is obvious over claim 7 of ‘862 in view of Smitherman. Instant claim 6 is obvious over claim 8 of ‘862 in view of Smitherman. Instant claim 7 is obvious over claim 9 of ‘862 in view of Smitherman. Instant claim 8 is obvious over claim 10 of ‘862 in view of Smitherman. Instant claim 9 is obvious over claim 11 of ‘862 in view of Smitherman. Instant claim 10 is obvious over claim 14 of ‘862 in view of Smitherman. Instant claim 11 is obvious over claim 15 of ‘862 in view of Smitherman. Instant claim 12 is obvious over claim 16 of ‘862 in view of Smitherman. Instant claim 13 is obvious over claim 20 of ‘862 in view of Smitherman Instant claim 14 is obvious over claim 21 of ‘862 in view of Smitherman Instant claim 15 is obvious over claim 22 of ‘862 in view of Smitherman. Instant claim 16 is obvious over claim 26 of ‘862 in view of Smitherman. Instant claim 17 is obvious over claim 27 of ‘862 in view of Smitherman. Instant claim 18 is obvious over claim 31 of ‘862 in view of Smitherman. Instant claim 19 is obvious over claim 32 of ‘862 in view of Smitherman. Instant claim 20 is obvious over claim 33 of ‘862 in view of Smitherman. Instant claim 21 is obvious over claim 34 of ‘862 in view of Smitherman. Regarding instant claim 22, claim 1 of ‘862 does not recite that the migraine associated with a concussion. Smitherman teaches that chronic daily headache (CDH) occurring subsequent to concussion is called a post-traumatic headache (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘862 by specifically treating a migraine subsequent to a concussion. The person of ordinary skill in the art would have been motivated by the teachings of Smitherman, who teaches that CDH encompasses migraines (page 1, Introduction, left column, Chronic daily headache paragraph 1), CDH can occur subsequent to a concussion (page 2, left column, Trauma, PTSD, and CDH, paragraph 1), and botulinum toxin is efficacious in the treatment of CDH (Opinion statement page 1). The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘862 is a botulinum toxin injection protocol. Regarding claim 23¸claim 1 of ‘862 does not recite that the migraine is associated with a post-traumatic brain injury that is also associated with post-traumatic stress disorder. However, Smitherman teaches migraines associated with PTSD as well as migraines associated with concussion and military service (page 2, left column, Trauma, PTSD, and CDH, paragraph 1). Therefore, it would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘862 to treat migraines in individuals with both post-traumatic brain injury such as concussion as well as PTSD, since migraines are associated with both. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘862 is a botulinum toxin injection protocol for treating migraines and Smitherman also teaches that botulinum toxin is efficacious in treating chronic daily headache (page 1, Opinion Statement), which includes migraines. Instant claim 24 is obvious over claim 35 of ‘862 in view of Smitherman. Instant claim 25 is obvious over claim 1 of ‘862 in view of Smitherman since Smitherman teaches that head injury is a secondary cause of CDH (page 6, Treatment of CDH (CM and CTTH), paragraph 1). A head injury that causes a CDH (encompasses migraines) is a type of post-traumatic brain injury. Claim 26 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,178,862 (hereafter ‘862) in view of Glenn et al. (Traumatic brain injury: a clinician’s guide to diagnosis, management, and rehabilitation. Cham: Springer International Publishing, 2019. 293-327). Instant claim 1 is drawn to a method for treating one or more symptoms of a migraine associated with a post-traumatic brain injury. Claim 1 of ‘862 recites a method for treating a migraine disorder. The method comprises a botulinum toxin injection protocol that is identical to instant claim 1. Claim 1 of ‘862 does not recite that the migraine is associated with post-concussion syndrome. Glenn teaches that mild traumatic brain injury can be associated with a variety of symptoms and the term “post-concussion syndrome” has been frequently used to describe the complex cognitive, physical and emotional complaints that can occur (page 309, left column, “Post-Concussion Symptoms,” paragraph 1). The most frequent complaints include headaches (page 309, “Post-Concussion Symptoms,” right column, paragraph 1). It would have been obvious to the person of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of claim 1 of ‘862 by treating a migraine associated with post-concussion syndrome. The person of ordinary skill in the art would have been motivated by the teaching of Glenn, who suggests that headaches are frequently experienced by individuals with post-concussion syndrome. The person of ordinary skill in the art would have had a reasonable expectation of success given that the method of claim 1 of ‘862 is a botulinum injection protocol for treating a migraine. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CANDICE LEE SWIFT whose telephone number is (571)272-0177. The examiner can normally be reached M-F 8:00 AM-4:30 PM (Eastern). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at (571)272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LOUISE W HUMPHREY/Supervisory Patent Examiner, Art Unit 1657 /CANDICE LEE SWIFT/Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Dec 12, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766170
PRODUCT DERIVED FROM RHODOCOCCUS RUBER, AND PHARMACEUTICAL USE THEREOF
2y 3m to grant Granted Oct 20, 2026
Patent 12716082
RECOMBINANT ENDOXYLANASES AND RELATED COMPOSITIONS AND METHODS OF USE
2y 7m to grant Granted Aug 25, 2026
Patent 12709595
NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN
3y 1m to grant Granted Aug 18, 2026
Patent 12692485
PEGYLATED KYNURENINASE ENZYMES AND USES THEREOF FOR THE TREATMENT OF CANCER
5y 9m to grant Granted Jul 28, 2026
Patent 12680091
ENGINEERED LIPASE VARIANTS
2y 3m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
95%
With Interview (+38.2%)
3y 2m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 131 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month